Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(1.78)
# 3,149
Out of 4,876 analysts
48
Total ratings
28.26%
Success rate
-5.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $22.89 | +336.87% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $2.95 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $13.32 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.31 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $12.02 | - | 1 | Dec 9, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $1.47 | - | 5 | Nov 26, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $2.38 | - | 9 | Nov 15, 2024 | |
| VSTM Verastem | Reiterates: Overweight | n/a | $4.24 | - | 1 | Oct 18, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Overweight | n/a | $18.08 | - | 1 | Jun 27, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | n/a | $5.79 | - | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $4.32 | +15.74% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.20 | +987.87% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $9.04 | -11.50% | 1 | Mar 20, 2023 |
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $22.89
Upside: +336.87%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.95
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $13.32
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.31
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.02
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.47
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.38
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.24
Upside: -
Dianthus Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $18.08
Upside: -
Jasper Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.79
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $4.32
Upside: +15.74%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $1.20
Upside: +987.87%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $9.04
Upside: -11.50%